http://www.zibb.com/all/theme/cq/OXiGENE+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Tue, 17 Nov 2009 12:30:24 GMTTue, 17 Nov 2009 12:30:24 GMT608831http://www.zibb.com/all/theme/cq/OXiGENE+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5675467/OXiGENE+Reports+Positive+Safety+Data+From+Phase+Trial+of+ZYBRESTAT+in+Non+Small+Cell+Lung+Cancer+at+the+AACR+NCI+EORTC+ConferenceOXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlledhttp://www.zibb.com/article/5675467/OXiGENE+Reports+Positive+Safety+Data+From+Phase+Trial+of+ZYBRESTAT+in+Non+Small+Cell+Lung+Cancer+at+the+AACR+NCI+EORTC+ConferenceOXiGENE IncorporatedTue, 17 Nov 2009 12:30:24 GMThttp://www.biospace.com/news_story.aspx?StoryID=159196&full=1SOUTH SAN FRANCISCO, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, and VaxGen, Inc.http://www.biospace.com/news_story.aspx?StoryID=159196&full=1OXiGENE IncorporatedThu, 15 Oct 2009 12:00:00 GMThttp://www.pharmaceutical-business-review.com/news/oxigene_agrees_to_acquire_symphony_vida_090706Including more than $12 million in unrestricted cash and all rights to oxi4503 and zybrestat for ophthalmologyhttp://www.pharmaceutical-business-review.com/news/oxigene_agrees_to_acquire_symphony_vida_090706OXiGENE IncorporatedMon, 06 Jul 2009 00:00:00 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/080903/20080903006067.html?.v=1Genelabs Technologies, Inc. Announces Appointment of Frederick W. Driscoll as President and CEO. - REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (NASDAQ:GNLB - News) today announced the appointment of Frederick W.http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/080903/20080903006067.html?.v=1OXiGENE IncorporatedWed, 03 Sep 2008 17:00:00 GMThttp://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-26-2001/0001521528&EDATE=Dramatic Visual Support for Mode of Action of Vascular Targeting Agent Combretastatin A4 Prodrug - Presentation at Bio 2001, San Diego, CA - WATERTOWN, Mass.http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-26-2001/0001521528&EDATE=OXiGENE Incorporatedhttp://www.asu.edu/studentaffairs/studentmedia/archives/1999/99fall/sp/sp990831/news10.htmlASU recently contributed to the fight against cancer and made progress in establishing itself as a research university--all because of the African bush willow.http://www.asu.edu/studentaffairs/studentmedia/archives/1999/99fall/sp/sp990831/news10.htmlOXiGENE Incorporatedhttp://www.zibb.com/article/5665580/OXiGENE+to+Present+at+American+Society+of+Hematology+and+AACR+NCI+EORTC+MeetingsOXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from preclinical studies of its vascular disrupting agent (VDA) drug candidate OXi4503 will be presented at thehttp://www.zibb.com/article/5665580/OXiGENE+to+Present+at+American+Society+of+Hematology+and+AACR+NCI+EORTC+MeetingsOXiGENE IncorporatedThu, 12 Nov 2009 16:00:42 GMThttp://www.zibb.com/article/5652934/OXiGENE+Reports+Third+Quarter+Financial+ResultsOXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and nine months ended September 30, 2009 and presented an update on recent clinical and corporatehttp://www.zibb.com/article/5652934/OXiGENE+Reports+Third+Quarter+Financial+ResultsOXiGENE IncorporatedMon, 09 Nov 2009 02:00:22 GMThttp://www.biospace.com/news_story.aspx?StoryID=158497&full=1SOUTH SAN FRANCISCO, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that its Chief Executive Officer, John A.http://www.biospace.com/news_story.aspx?StoryID=158497&full=1OXiGENE IncorporatedThu, 08 Oct 2009 12:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=146174&full=1WALTHAM, Mass., June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the appointment of Peter J. Langecker, M.D., Ph.D., as Executive Vice President and Chief Development Officer. Dr.http://www.biospace.com/news_story.aspx?StoryID=146174&full=1OXiGENE IncorporatedWed, 17 Jun 2009 12:00:00 GMThttp://www.zibb.com/article/5675426/OXiGENE+Down+Since+SmarTrend+s+Sell+RecommendationSmarTrend, our proprietary pattern recognition system, called a Downtrend for OXiGENE (NASDAQ:OXGN) on July 16, 2009 at $1.59. Since then, OXiGENE has returned 9.8% as of today's recent price of $1.43. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial. Writehttp://www.zibb.com/article/5675426/OXiGENE+Down+Since+SmarTrend+s+Sell+RecommendationOXiGENE IncorporatedTue, 17 Nov 2009 12:09:53 GMThttp://www.zibb.com/article/5654905/OXiGENE+Down+Since+SmarTrend+s+Sell+RecommendationSmarTrend, our proprietary pattern recognition system, called a Downtrend for OXiGENE (NASDAQ:OXGN) on July 16, 2009 at $1.59. Since then, OXiGENE has returned 27.4% as of today's recent price of $1.15. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial. Writehttp://www.zibb.com/article/5654905/OXiGENE+Down+Since+SmarTrend+s+Sell+RecommendationOXiGENE IncorporatedMon, 09 Nov 2009 13:56:52 GMThttp://www.zibb.com/article/5645016/OXiGENE+Inc+OXGN+Corporate+Event+Announcement+NoticeOXiGENE, Inc. (OXGN) Expected next earnings release: Announcement date: 11/9/2009 - Before Market Earnings Quarter: Q3 Announcement Status: Verified Expected next investor conference call information: Conference Call Date: 11/9/2009 Conference Call Time (ET): 9:00 AM Conference Call URL:http://www.zibb.com/article/5645016/OXiGENE+Inc+OXGN+Corporate+Event+Announcement+NoticeOXiGENE IncorporatedWed, 04 Nov 2009 21:24:49 GMThttp://www.zibb.com/article/5598134/OXiGENE+Down+Since+SmarTrend+s+Sell+RecommendationSmarTrend, our proprietary pattern recognition system, called a Downtrend for OXiGENE (NASDAQ:OXGN) on July 16, 2009 at $1.59. Since then, OXiGENE has returned 15% as of Friday's recent price of $1.35. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial. Writehttp://www.zibb.com/article/5598134/OXiGENE+Down+Since+SmarTrend+s+Sell+RecommendationOXiGENE IncorporatedSun, 18 Oct 2009 13:42:36 GMThttp://www.zibb.com/article/5583268/OXiGENE+s+CEO+resignsOXiGENE, a clinical-stage biopharmaceutical company, has reported that its CEO, John Kollins, has resigned from his position with the company and as a member of the board of directors in order to pursue other interests. Peter Langecker, executive vice president and chief development officer, willhttp://www.zibb.com/article/5583268/OXiGENE+s+CEO+resignsOXiGENE IncorporatedMon, 12 Oct 2009 05:04:08 GMThttp://www.pharmaceutical-business-review.com/news/oxigene_initiates_phaseii_trial_of_zybrestat_090625OXiGENE has initiated the phase-II study of vascular disrupting agent drug candidate, Zybrestat for ophthalmology in patients with polypoidal choroidal vasculopathy (PCV).http://www.pharmaceutical-business-review.com/news/oxigene_initiates_phaseii_trial_of_zybrestat_090625OXiGENE IncorporatedThu, 25 Jun 2009 00:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=114049&full=1WALTHAM, Mass., Oct. 23, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM:OXGN - News) (Stockholm:OXGN.ST - News) announced today that its Board of Directors has appointed John A. Kollins, the Company's current Chief Operating Officer, to the positions of Chief Executive Officer and Director.http://www.biospace.com/news_story.aspx?StoryID=114049&full=1OXiGENE IncorporatedThu, 23 Oct 2008 12:00:00 GMThttp://www.zibb.com/article/5659814/OXiGENE+Inc+OXGN+Corporate+Event+Announcement+NoticeOXiGENE, Inc. (OXGN) Expected next earnings release: Announcement date: 3/18/2010 - Before Market Earnings Quarter: Q4 Announcement Status: Unconfirmed Expected next investor conference call information: Conference Call Date: 11/9/2009 Conference Call Time (ET): 9:00 AM Conference Call URL:http://www.zibb.com/article/5659814/OXiGENE+Inc+OXGN+Corporate+Event+Announcement+NoticeOXiGENE IncorporatedTue, 10 Nov 2009 21:32:09 GMThttp://www.zibb.com/article/5656473/OXiGENE+to+Present+at+Merriman+Curhan+Ford+and+Lazard+Healthcare+ConferencesOXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that OXiGENE Management will present a corporate overview and update at the Merriman Curhan Ford Investor Summit at 12:00 noonhttp://www.zibb.com/article/5656473/OXiGENE+to+Present+at+Merriman+Curhan+Ford+and+Lazard+Healthcare+ConferencesOXiGENE IncorporatedTue, 10 Nov 2009 02:00:19 GMThttp://www.zibb.com/article/5656061/OXiGENE+Inc+OXGN+Corporate+Event+Announcement+NoticeOXiGENE, Inc. (OXGN) Expected next earnings release: Announcement date: 11/9/2009 - Before Market Earnings Quarter: Q3 Announcement Status: Verified Expected next investor conference call information: Conference Call Date: 11/9/2009 Conference Call Time (ET): 9:00 AM Conference Call URL:http://www.zibb.com/article/5656061/OXiGENE+Inc+OXGN+Corporate+Event+Announcement+NoticeOXiGENE IncorporatedMon, 09 Nov 2009 21:06:33 GMThttp://www.zibb.com/article/5653524/OXiGENE+Inc+posts+net+loss+of+USD+m+for+third+quarter+ofBiopharmaceutical company OXiGENE Inc (Nasdaq:OXGN) (Stockholm:OXGN) announced on Monday its consolidated net loss of USD6.9m for the third quarter of 2009. A This is an improvement as compared with a consolidated net loss of USD7.1m for the same period in 2008. A Consolidated net loss for thehttp://www.zibb.com/article/5653524/OXiGENE+Inc+posts+net+loss+of+USD+m+for+third+quarter+ofOXiGENE IncorporatedMon, 09 Nov 2009 07:46:10 GMThttp://www.zibb.com/article/5637604/OXiGENE+Announces+Third+Quarter+Earnings+Conference+Call+and+WebcastOXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report third quarter 2009 results on Monday, November 9th, 2009. A conference call and webcast hosted by OXiGENE management will begin athttp://www.zibb.com/article/5637604/OXiGENE+Announces+Third+Quarter+Earnings+Conference+Call+and+WebcastOXiGENE IncorporatedTue, 03 Nov 2009 02:00:13 GMThttp://www.zibb.com/article/5593843/OXiGENE+to+acquire+VaxGenOXiGENE, Inc. has entered into a definitive agreement to acquire all the outstanding shares of VaxGen, Inc., a biopharmaceutical company, in exchange for common shares. The transaction is valued at approximately $22 million. OXiGENE is a clinical-stage biopharmaceutical company developing novelhttp://www.zibb.com/article/5593843/OXiGENE+to+acquire+VaxGenOXiGENE IncorporatedThu, 15 Oct 2009 15:13:17 GMThttp://www.zibb.com/article/5591977/OXiGENE+to+Acquire+VaxGen+in+a+Stock+for+Stock+MergerAcquisition to Add Approximately $33 Million in Cash to OXiGENE's Balance Sheet Conference Call Today at 9:00 AM Eastern SOUTH SAN FRANCISCO, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novelhttp://www.zibb.com/article/5591977/OXiGENE+to+Acquire+VaxGen+in+a+Stock+for+Stock+MergerOXiGENE IncorporatedThu, 15 Oct 2009 06:01:36 GMThttp://www.zibb.com/article/5583597/OXiGENE+Announces+Data+Presentation+At+AACR+EORTC+NCI+ConferenceOXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that interim data from its randomized, controlled, Phase 2 study of ZYBRESTAT(TM) in combination with Avastin(R) and chemotherapy inhttp://www.zibb.com/article/5583597/OXiGENE+Announces+Data+Presentation+At+AACR+EORTC+NCI+ConferenceOXiGENE IncorporatedMon, 12 Oct 2009 08:02:44 GMT